Development of IL1RAP antibodies targeting AML CS
$223,524N43FY2014CANIH
Cellerant Therapeutics, Inc., San Carlos CA
Investigators
Abstract
Development of IL1RAP antibodies targeting AML CS
View original record on NIH RePORTER →Cellerant Therapeutics, Inc., San Carlos CA
Development of IL1RAP antibodies targeting AML CS
View original record on NIH RePORTER →